Pages that link to "Q34976915"

The following pages link to Pharmacogenomics: the genetics of variable drug responses (Q34976915):

Displaying 43 items.

• Role of genomics in eliminating health disparities (Q26782236) (← links)
• Cardiovascular pharmacogenomics: current status and future directions (Q26801183) (← links)
• Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: a paradigm shift (Q28088445) (← links)
• An ontology-based, mobile-optimized system for pharmacogenomic decision support at the point-of-care (Q28538389) (← links)
• Genetics and cardiovascular disease: a policy statement from the American Heart Association. (Q30418104) (← links)
• Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network (Q31043647) (← links)
• Mapping genes that predict treatment outcome in admixed populations (Q34348337) (← links)
• Personalizing health care: feasibility and future implications (Q34938911) (← links)
• Pharmacogenomics: will the promise be fulfilled? (Q34994860) (← links)
• A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes (Q35783016) (← links)
• Genes and Cardiovascular Disease: Where do we go from here? (Q36331319) (← links)
• Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval (Q37154348) (← links)
• Clinical Considerations of Heritable Factors in Common Heart Failure (Q37970334) (← links)
• The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy (Q38003702) (← links)
• Strategies for personalized medicine-based research and implementation in the clinical workflow (Q38036525) (← links)
• Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors (Q38048837) (← links)
• To replicate or not to replicate: the case of pharmacogenetic studies: Establishing validity of pharmacogenomic findings: from replication to triangulation. (Q38130427) (← links)
• Single nucleotide polymorphism and its dynamics for pharmacogenomics (Q38244756) (← links)
• Clinical association between pharmacogenomics and adverse drug reactions (Q38431150) (← links)
• Through a glass darkly: economics and personalised medicine (Q39145520) (← links)
• Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age. (Q39756044) (← links)
• Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits (Q41945248) (← links)
• Perspective on the Genetic Response to Antiparasitics: A Review Article (Q47308561) (← links)
• Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis (Q47786696) (← links)
• Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer. (Q48120168) (← links)
• Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records (Q49931634) (← links)
• Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. (Q52705350) (← links)
• Network, Transcriptomic and Genomic Features Differentiate Genes Relevant for Drug Response (Q57491987) (← links)
• Frequencies of poor metabolizer alleles of 12 pharmacogenomic actionable genes in Punjabi Sikhs of Indian Origin (Q57794673) (← links)
• Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant (Q57807746) (← links)
• Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives (Q60950044) (← links)
• Point mutation detection by economic HRM protocol primer design (Q64062253) (← links)
• Mouse Systems Genetics as a Prelude to Precision Medicine (Q89614848) (← links)
• Precision Medicine in Non-Communicable Diseases (Q89658254) (← links)
• A stepwise approach to implementing pharmacogenetic testing in the primary care setting (Q90548092) (← links)
• Genome-wide Association Studies in Ancestrally Diverse Populations: Opportunities, Methods, Pitfalls, and Recommendations (Q90677825) (← links)
• Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry (Q91687653) (← links)
• Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications (Q91906258) (← links)
• Copy number variation profiling in pharmacogenetics CYP-450 and GST genes in Colombian population (Q92029718) (← links)
• A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study (Q92136058) (← links)
• A Decision-Theoretic Approach to Panel-Based, Preemptive Genotyping (Q92894202) (← links)
• Receptor variants and the development of centrally acting medications (Q95579816) (← links)
• Pharmacogenomics Instruction Depth, Extent, and Perception in US Medical Curricula (Q98386840) (← links)